Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Learn more about:
Related Clinical Trial
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Investigating Meningococcal Vaccines in Adults Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals’ Hib-MenC & to Evaluate Persistence up to 5 Years. Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals’ Hib-MenC Primary & Booster Immunogenicity Study of GSK Biologicals’ Hib-MenC Versus a Licensed Men-C Vaccine Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine Dose Comparison Study of Menactra® in US Children Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals’ Hib-MenCY-TT Vaccine Compared to ActHIB Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) Neisseria Meningitidis Burden of Disease Study Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers

Recruitment Information


Administrative Informations